ORYZON capta 30 millones de euros en una ampliación de capital internacional

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44% discount to the 5-day volume-weighted average price (VWAP) of €2.779 per share prior to April 22, 2025, and a 19.38% discount to the April 22 closing price of €2.915. The offering, which was structured as straight equity with no warrants attached, attracted strong demand and was significantly oversubscribed. A US-based institutional investor anchored the round with a €15 million order, with the remaining demand filled by investors across the US, Europe, and Spain. The capital increase was capped at €30 million by the company’s Board of Directors.

Maxim (U.S.), All-Invest (EU/UK), and Singular Bank (Spain) acted as bookrunners. Banco Sabadell, S.A. acted as the Settlement and Technical Pre-financing Agent for the Capital Increase, while Gómez-Acebo & Pombo Abogados, S.L.P. (Spanish law) and Gibson, Dunn & Crutcher LLP (U.S. law) served as legal advisors to the Company, and Loeb & Loeb LLP acted as U.S. legal counsel to Maxim Group LLC.

The funds raised will be used to: 

• Advance the clinical development of vafidemstat for the treatment of aggression in CNS disorders such as Borderline Personality Disorder (BPD) and Autism Spectrum Disorder (ASD)
• Expand ongoing clinical programs in oncology and hematology
• Support CMC activities and preparations for Phase IIb-III trials, as well as other regulatory initiatives
• Strengthen the company's balance sheet to support future partnership or M&A negotiations
• Cover general administrative expenses and financial obligations
• Enhance legal and audit readiness for a potential dual listing on Nasdaq

Dr. Carlos Buesa, CEO of Oryzon, CEO of Oryzon, commented: “This financing marks a key milestone that enables us to continue progressing our clinical programs with vafidemstat in aggression-related CNS disorders and to further develop our oncology and hematology pipeline. It also reinforces our financial position, supporting strategic conversations with investors and potential partners.